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About a decade ago, triggered by unexplained growth 
and variability in cardiovascular testing,1 eﬀ orts to 
redeﬁ ne imaging quality led to an appreciation of the 
importance of selecting the right test for the right 
patient (ie, giving rise to appropriate use criteria) 
and measuring the eﬀ ect of testing on outcomes, in 
addition to measures such as image acquisition and 
interpretation.2 Although appropriate use criteria 
are now an established part of evidence-based 
cardiovascular care, imaging outcomes have not been 
deﬁ ned in a more meaningful way, partly because of the 
many steps needed to translate test data into knowledge 
(ie, diagnostic thinking), action (ie, treatments), and 
ultimately outcomes.
Nevertheless, there have been strong calls to explore 
the downstream consequences of imaging as a 
necessary step in more fully understanding its risks and 
beneﬁ ts, which would then help to establish scenarios 
in which imaging does, and does not, add value.3 This 
task has been made more diﬃ  cult in the era following 
the COURAGE4 and FAME5 trials, in which the diagnosis 
of anatomical coronary artery disease has been 
uncoupled from a need for revascularisation, and in the 
post-CONFIRM era,6 in which non-obstructive coronary 
artery disease is recognised to be a powerful predictor of 
future events.
A few trials have been done to rise to this challenge in 
the primary prevention area and in the triage of acute 
chest pain, variously using risk factor burden, clinical 
events, and eﬃ  ciency as endpoints. Randomised trial 
data assessing the eﬀ ect of testing in the very large 
stable chest pain population have been scarce, but are 
now present in the form of two new large studies—
the Computed Tomography Coronary Angiography in 
Patients with Suspected Angina due to Coronary Heart 
Disease: the Scottish Computed Tomography of the 
HEART (SCOT-HEART) trial7 reported by David Newby 
and colleagues in The Lancet, and the PROspective 
Multicenter Imaging Study for Evaluation of Chest Pain 
(PROMISE) trial.8
In SCOT-HEART, 4146 patients completing an 
assessment for stable chest pain were randomly 
assigned to CT coronary angiography (CTCA) in addition 
to usual care or to usual care alone, which generally 
included an exercise treadmill test. The trial’s primary 
endpoint, certainty of the attribution of symptoms 
to angina due to presence of coronary artery disease, 
showed an increase in the CTCA group (relative risk 
1·79, 95% CI 1·62–1·96), as did the closely related 
secondary endpoint of certainty of diagnosis of coronary 
artery disease (2·56, 2·33–2·79). Additional secondary 
endpoints included diagnostic reclassiﬁ cation and 
changes in diagnostic and therapeutic approaches, 
which all happened more frequently in the CTCA 
group. Although investigators recorded no diﬀ erences 
in the frequency or stability of angina, rates of 
revascularisation, or admittance to hospital, there 
was a non-signiﬁ cant reduction in the rate of death or 
myocardial infarction in the CTCA group. This latter 
ﬁ nding is intriguing but should be treated with caution: 
it was one of 22 prespeciﬁ ed secondary endpoints, and 
the absolute diﬀ erence between the two groups was 
only 16 events. 
Because randomised trials of cardiovascular imaging 
are fairly new, much can be learned from the well-done 
SCOT-HEART study to guide clinical care and future 
research. Many crucial questions are raised: ﬁ rst, in 
the absence of a feasible placebo strategy, how can 
imaging studies prevent or control bias in favour 
of the intervention? In SCOT-HEART, CTCA created 
greater diagnostic certainty in CT readers than in 
non-reader clinicians. Second, should imaging ﬁ ndings 
be prospectively linked to mandated care algorithms? 
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Incomplete abortion is deﬁ ned as the presence of 
retained products of conception with no well-deﬁ ned 
gestation sac. It is a potentially life-threatening 
condition that without well-timed and proper 
treatment can lead to severe complications such as 
haemorrhagic shock, sepsis, and death. Abortion-
related complications still contribute substantially 
to maternal morbidity and mortality in sub-Saharan 
Africa.1 Backup treatment of complications from 
unsafe abortion and spontaneous abortion (post-
abortion care) is an eﬀ ective intervention to reduce 
maternal mortality. The post-abortion care model 
consists of emergency treatment of abortion-
related complications, post-abortion contraceptive 
counselling, and free contraception.2 The lack of 
physicians in many low-income countries restricts 
women’s access to post-abortion care. In Africa, the 
shortage of trained health-care providers is greatest in 
rural and remote areas where maternal mortality and 
morbidity is highest.3 In The Lancet, Marie Klingberg-
Allvin and colleagues4 report the results of a multicentre 
equivalence randomised controlled trial to examine 
Treatment with misoprostol by midwives is safe and eﬀ ective
Because a test can only aﬀ ect outcomes by changing care, 
the failure to follow best practices, or the ineﬀ ectiveness 
of treatments, can be falsely attributed to the test. 
Indeed in the PARR-2 trial,9 although performance of 
a cardiac PET viability scan did not change outcomes in 
patients with heart failure overall, patients who received 
PET-guided care (and not just a scan) had fewer events. 
SCOT-HEART bypassed this issue by using the upstream 
outcome of diagnostic certainty, but clinical events 
remain the preferred evidentiary standard.
Third, if intermediate outcomes are used, what 
outcomes are most important to both patients and 
clinicians in guiding test selection? Diagnostic thinking 
is important, and might change processes of care, 
as shown in SCOT-HEART, but other unexamined 
parameters such as eﬃ  ciency, safety, and avoidance of 
unnecessary invasive procedures might be equally, if 
not more, salient. Finally, although the very low rate 
of clinical events in SCOT-HEART (ie, cardiovascular 
death or myocardial infarction were reported in just 
68 [1·6%] participants in 1·7 years of follow-up) is 
encouraging in documenting an excellent prognosis 
for patients with new-onset stable chest pain receiving 
contemporary care, to show a diﬀ erence in patient 
outcomes with diﬀ erent testing strategies in view of 
this excellent prognosis would need a large incremental 
test eﬀ ect driving diﬀ erences in downstream care, an 
extremely large study sample, prolonged follow-up, or a 
combination of these factors.
SCOT-HEART7 provides important data regarding 
the eﬀ ect of the addition of a new technology to usual 
care, and explores new methods for the theory and 
practice of imaging outcomes research. However, more 
work is needed in this new specialty before the value of 
cardiovascular imaging can be fully understood.
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